Maia Biotechnology Inc (MAIA)
| Sector • Healthcare Industry • Major Pharmaceutical Preparations |
| Industry • Major Pharmaceutical Preparations |
| Sector • Healthcare |
The company announced operating surplus of $8.53763 millions, in the fourth quarter of 2022 financial report
company delivered fourth quarter of 2022 operating surplus of $8.53763 millions
Published Mar 25 2023
Goran Soko / CSIMarket.com Contributer
![pills_blue_By_Tom_Varco_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons](../news/img/healthcare/Autosample_takes_a_By_Hey_Paul_(originally_posted_to_Flickr_as_image4)_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons.jpg "pills_blue_By_Tom_Varco_(Own_work)_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons")
The Major Pharmaceutical Preparations sector reporters start to digest the fourth quarter of 2022 results. Now those reporters observe operating surplus of $8.53763 millions, from the company, which has not stated any top-line thus far, for the own October to December 31 2022 quarter. The company resumes to be profitable and actually did advance net profits from $0.000 millions, in the fourth quarter of , to $8.210 millions, in the October to December 31 2022 interval.
Maia Biotechnology Inc is expected to report next financial earnings on August 21, 2023.